The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis

  1. Qing-Jun Meng1,6
  1. 1Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom;
  2. 2Department of Biophysics and Biochemistry, Graduate School of Science, University of Tokyo, Tokyo 113-0033, Japan;
  3. 3Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan;
  4. 4University of California at Irvine, Irvine, California 92697, USA;
  5. 5Department of Genetics, Center for Biomedical Genetics, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands

    Abstract

    The disruption of the NRF2 (nuclear factor erythroid-derived 2-like 2)/glutathione-mediated antioxidant defense pathway is a critical step in the pathogenesis of several chronic pulmonary diseases and cancer. While the mechanism of NRF2 activation upon oxidative stress has been widely investigated, little is known about the endogenous signals that regulate the NRF2 pathway in lung physiology and pathology. Here we show that an E-box-mediated circadian rhythm of NRF2 protein is essential in regulating the rhythmic expression of antioxidant genes involved in glutathione redox homeostasis in the mouse lung. Using an in vivo bleomycin-induced lung fibrosis model, we reveal a clock “gated” pulmonary response to oxidative injury, with a more severe fibrotic effect when bleomycin was applied at a circadian nadir in NRF2 levels. Timed administration of sulforaphane, an NRF2 activator, significantly blocked this phenotype. Moreover, in the lungs of the arrhythmic ClockΔ19 mice, the levels of NRF2 and the reduced glutathione are constitutively low, associated with increased protein oxidative damage and a spontaneous fibrotic-like pulmonary phenotype. Our findings reveal a pivotal role for the circadian control of the NRF2/glutathione pathway in combating oxidative/fibrotic lung damage, which might prompt new chronotherapeutic strategies for the treatment of human lung diseases, including idiopathic pulmonary fibrosis.

    Keywords

    Footnotes

    • Received December 23, 2013.
    • Accepted February 14, 2014.

    This article, published in Genes & Development, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0.

    | Table of Contents
    OPEN ACCESS ARTICLE

    G&D Most Read

    View all ...

    Life Science Alliance